Bavarian Nordic A/S

Bavarian Nordic A/S

BVNRY - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$2.75B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Bavarian Nordic A/SBavarian Nordic A/S12.4-12%0.5-

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$2.75 Billion
Enterprise Value$2.10 Billion
Earnings per Share$5.66
Beta0.94
Outstanding Shares227,883,789

Return

Return on Equity11.79%ROE
Return on Assets10.58%
Return on Invested Capital13.90%

Valuation & Multiples

P/E Ratio12.44P/E Ratio
PEG11.81PEG
Price to Sales0.46Price to Sales
Price to Book Ratio0.21Price to Book Ratio
Enterprise Value to Revenue0.35
Enterprise Value to EBIT1.1
Enterprise Value to Net Income1
Total Debt to Enterprise0.06
Debt to Equity0.01Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 21, 2026
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
$228.49 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Bavarian Nordic A/S

1,906 employees
CEO: Paul John Chaplin

Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for sm...